Compare ADMA Biologics Inc (ADMA) vs AST SpaceMobile Inc (ASTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs AST SpaceMobile Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while AST SpaceMobile Inc trades at $71.6 (market cap $20.54B). The key difference: AST SpaceMobile Inc is far larger — about 9.4× ADMA Biologics Inc's market cap, and AST SpaceMobile Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | ASTS | |
|---|---|---|
Market Cap | $2.18B | $20.54B |
Sector | Health | Media |
52-Week High | $20.38 | $133.09 |
52-Week Low | $7.60 | $36.91 |
Enterprise Value | $2.25B | $21.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
AST SpaceMobile (ASTS) trades at $71.94, up 6.8% on the day, reflecting strong momentum despite recent earnings misses. The stock shows a bullish technical signal with key resistance at $73 and support at $69. Fundamentally, revenue grew to $71M in 2025, but net losses persist at -$342M, with a negative net margin of -482.17%. The company maintains a $1.3B backlog and raised its 2026 revenue guidance to $150M-$200M, indicating growth potential amid high cash burn.
Outlook: ASTS offers speculative upside driven by satellite network expansion and partnerships, with a consensus price target of $85.45 (19% upside). Risks include sustained losses, execution delays, and high valuation (P/S of 230.94). Investors should weigh growth prospects against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →
